MedTrace Logo

Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD

NCT02680756 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2020-11-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the efficacy of ferric maltol and intravenous iron (IVI) Ferric Carboxy Maltose in the treatment of iron deficiency anaemia (IDA) and subsequent maintenance of haemoglobin in subjects with Inflammatory Bowel Disease (IBD).

Conditions

Interventions

DRUG

Ferric Maltol

DRUG

Ferric Carboxy Maltose

Sponsors & Collaborators

  • Shield Therapeutics

    lead INDUSTRY

Principal Investigators

  • Jackie Mitchell, PhD · Shield Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2018-10-31
Completion
2019-01-31

Countries

  • United States
  • Belgium
  • France
  • Germany
  • Hungary
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02680756 on ClinicalTrials.gov